Todd R. Golub
Broad Institute
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Melanoma and MAPK Pathways
Strong evidence · 3 supporting papers · latest 2026
Cancer Research and Treatments
Strong evidence · 3 supporting papers · latest 2026
Peptidase Inhibition and Analysis
Solid evidence · 1 supporting paper · latest 2025
Histone Deacetylase Inhibitors Research
Solid evidence · 1 supporting paper · latest 2025
Epigenetics and DNA Methylation
Solid evidence · 1 supporting paper · latest 2025
Protein Degradation and Inhibitors
Solid evidence · 3 supporting papers · latest 2026
Protein Tyrosine Phosphatases
Solid evidence · 1 supporting paper · latest 2025
RNA Research and Splicing
Solid evidence · 1 supporting paper · latest 2025
Publications (18)
Discovery of chromatin-based determinants of azacytidine and decitabine anti-cancer activity
2025DOIPMID 40766713
O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis
2025DOI
Abstract B019: O-mannosylation represents a therapeutic opportunity in BRAF fusion protein oncogenesis
2025DOI
Generative Design of Cell Type-Specific RNA Splicing Elements for Programmable Gene Regulation
2025DOIPMID 41279721
Abstract 495: Single-cell multiomic drug response profiling of PRISM-multiplexed cancer cell lines sequenced with SBX.
2026DOI
Abstract B026: O-mannosylation and protein maturation checkpoints represent therapeutic opportunities in BRAF fusion protein oncogenesis
2026DOI
O-mannosylation and protein maturation checkpoints represent therapeutic opportunities in BRAF fusion protein oncogenesis
2026DOIPMID 42714308
Abstract 553: Selective induction of cuproptosis in vivo by a soluble Elesclomol analog.
2026DOI
Dynamic inositol pyrophosphate synthesis is a targetable therapeutic opportunity in ovarian cancer
2026DOI
Abstract 7265: MBCproject: multi-omic profiling of metastatic breast cancer evolution through patient-partnered research
2026DOI
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity
2026DOIPMID 41955354
Abstract PS4-04-19: A nucleic acid sensing system for selective therapeutic protein expression in breast cancer
2026DOI
PD21-12 TUMOR MICROENVIRONMENTAL NRG1 DRIVES RESISTANCE TO PI3K/AKT PATHWAY INHIBITION IN PROSTATE CANCER
2026DOI
Tumor microenvironmental NRG1 activation of HER3 as a driver of resistance to PI3K pathway inhibition in prostate cancer.
2026DOI
Author Correction: Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors
2026DOIPMID 42215493
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Broad Institute
- Dana-Farber Cancer Institute
Source: OpenAlex · retrieved 2026-09-29